Olesoxime

Summary

Olesoxime (CHEMBL3545254) is a phase-3 clinical-stage small molecule; indicated across 5 conditions including amyotrophic lateral sclerosis and metabolic dysfunction-associated steatotic liver disease.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Small molecule
• Indications: 5 conditions
• Clinical trials: 8
• Chemistry: 399.7 Da · C27H45NO

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL3545254
Name	Olesoxime
Type	Small molecule
Max phase	3
FDA approved	no
PubChem CID	76971721
Molecular formula	C27H45NO
Molecular weight	399.7
InChIKey	QNTASHOAVRSLMD-GYKMGIIDSA-N

SMILES: C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CCC4=CC(=NO)CC[C@]34C)C

IUPAC name: N-[(8S,9S,10R,13R,14S,17R)-10,13-dimethyl-17-[(2R)-6-methylheptan-2-yl]-1,2,6,7,8,9,11,12,14,15,16,17-dodecahydrocyclopenta[a]phenanthren-3-ylidene]hydroxylamine

Also known as: oxime, NSC-21311, Olesoxima, Olesoxime, TRO-19622, TRO19622, OLESOXIME

Patent coverage: 134 distinct patent families (429 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

5 indications (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
amyotrophic lateral sclerosis	3	MONDO:0004976	MONDO:0004976
metabolic dysfunction-associated steatotic liver disease	2	MONDO:0013209	EFO:0003095
peripheral neuropathy	2	MONDO:0005244	EFO:0003100
spinal muscular atrophy	2	MONDO:0001516	EFO:0008525
relapsing-remitting multiple sclerosis	1	MONDO:0005314	EFO:0003929

Clinical trials

Total trials: 8.

Phase distribution

Phase	Trials
PHASE2	4
PHASE1	2
PHASE3	1
PHASE2/PHASE3	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT00868166	PHASE3	COMPLETED	Safety and Efficacy of TRO19622 as add-on Therapy to Riluzole Versus Placebo in Treatment of Patients Suffering From ALS
NCT01285583	PHASE2/PHASE3	COMPLETED	Safety Extension Study of TRO19622 in ALS
NCT00666016	PHASE2	COMPLETED	Exploratory Study to Assess the Short Term Effect on Liver Enzymes and the Safety of TRO19622 in Patients With Non-Alcoholic Steatohepatitis (NASH)
NCT00876538	PHASE2	COMPLETED	Effect of TRO19622 in the Treatment of Patients With Chemotherapy Induced Peripheral Neuropathy
NCT01302600	PHASE2	COMPLETED	Safety and Efficacy of Olesoxime (TRO19622) in 3-25 Years SMA Patients.
NCT02628743	PHASE2	COMPLETED	A Study to Evaluate Long Term Safety, Tolerability, and Effectiveness of Olesoxime in Patients With Spinal Muscular Atrophy (SMA)
NCT01808885	PHASE1	COMPLETED	Safety Study of Olesoxime in Patients With Stable Relapsing Remitting Multiple Sclerosis Treated With Interferon Beta.
NCT02835976	PHASE1	COMPLETED	A Study of the Excretion Balance of Radiocarbon and the Pharmacokinetics and Metabolic Profile of TRO19622 (Olesoxime)

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).